Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:39:18 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SYRS - SYROS PHARMACEUTICALS INC - http://www.syros.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SYRS - Q2.54.95·5.910.15.04-0.06-1.244.52035465.03  5.1203  4.998.17  2.0902Apr 26Apr 0215 min RT 2¢

Recent Trades - Last 10 of 546
Time ETExPriceChangeVolume
17:30:02Q4.97-0.132
17:12:19Q5.160.061
16:16:01Q5.04-0.0623
16:10:54Q5.150.051
16:05:52Q4.97-0.131
16:00:05Q5.04-0.0619
16:00:00Q5.04-0.06300
16:00:00Q5.04-0.06100
16:00:00Q5.04-0.06100
16:00:00Q5.04-0.06100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-02 16:30U:SYRSNews ReleaseSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-27 07:30U:SYRSNews ReleaseSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
2024-03-25 07:00U:SYRSNews ReleaseSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
2024-03-20 07:00U:SYRSNews ReleaseSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
2024-02-27 07:00U:SYRSNews ReleaseSyros to Participate in TD Cowen 44th Annual Health Care Conference
2024-01-08 07:00U:SYRSNews ReleaseSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
2023-12-19 07:27U:SYRSNews ReleaseSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
2023-12-06 07:00U:SYRSNews ReleaseSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
2023-11-21 07:30U:SYRSNews ReleaseSyros to Participate in Upcoming Investor Conferences
2023-11-14 07:30U:SYRSNews ReleaseSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
2023-11-07 07:30U:SYRSNews ReleaseSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
2023-10-02 08:45U:SYRSNews ReleaseSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
2023-09-07 16:30U:SYRSNews ReleaseSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-08 07:30U:SYRSNews ReleaseSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
2023-08-04 16:30U:SYRSNews ReleaseSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-01 07:30U:SYRSNews ReleaseSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
2023-07-05 16:30U:SYRSNews ReleaseSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-08 07:30U:SYRSNews ReleaseSyros to Present at Sidoti June 2023 Virtual Small-Cap Conference
2023-06-01 16:30U:SYRSNews ReleaseSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-25 17:05U:SYRSNews ReleaseSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting